Segall Bryant & Hamill, LLC Tg Therapeutics, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.07 Billion
- Q4 2024
A detailed history of Segall Bryant & Hamill, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 79,518 shares of TGTX stock, worth $2.46 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
79,518
Previous 52,390
51.78%
Holding current value
$2.46 Million
Previous $1.23 Million
95.35%
% of portfolio
0.03%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding TGTX
# of Institutions
371Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$482 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$352 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$284 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$98.6 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.79MShares$86.3 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.49B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...